Cargando…

Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma

Patients with multiple myeloma commonly develop focal osteolytic bone disease, as well as generalised osteoporosis. The mechanisms underlying the development of osteoporosis in patients with myeloma are poorly understood. Although disruption of the RANKL/OPG pathway has been shown to underlie format...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buckle, Clive Henry, De Leenheer, Evy, Lawson, Michelle Anne, Yong, Kwee, Rabin, Neil, Perry, Mark, Vanderkerken, Karen, Croucher, Peter Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430669/ https://www.ncbi.nlm.nih.gov/pubmed/22952578 http://dx.doi.org/10.1371/journal.pone.0041127

Ejemplares similares

Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells
por: Faraahi, Z., et al.
Publicado: (2019)

Exosomes in multiple myeloma: from bench to bedside
por: Menu, Eline, et al.
Publicado: (2022)

PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma
por: McCourt, Orla, et al.
Publicado: (2020)

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma
por: Parrondo, Ricardo D, et al.
Publicado: (2019)

Corrigendum to “Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells” [Bone 122 (May 2019) 82–92]
por: Faraahi, Z., et al.
Publicado: (2019)

Adaptation of the PERCEPT myeloma prehabilitation trial to virtual delivery: changes in response to the COVID-19 pandemic
por: McCourt, Orla, et al.
Publicado: (2022)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche
por: Lawson, Michelle A., et al.
Publicado: (2015)

The genetic landscape of 5T models for multiple myeloma
por: Maes, Ken, et al.
Publicado: (2018)

ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo
por: Lath, Darren L., et al.
Publicado: (2018)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
por: Bieghs, Liesbeth, et al.
Publicado: (2010)

Multiple myeloma and physical activity
por: Lecat, Catherine S. Y., et al.
Publicado: (2021)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
por: Kolovos, Spyros, et al.
Publicado: (2019)

Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
por: Xu, Song, et al.
Publicado: (2018)

Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo
por: Vitovski, Srdjan, et al.
Publicado: (2012)

Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing
por: Malhotra, Karan, et al.
Publicado: (2016)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
por: Favreau, Mérédis, et al.
Publicado: (2016)

Polycomb Target Genes Are Silenced in Multiple Myeloma
por: Kalushkova, Antonia, et al.
Publicado: (2010)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
por: Wang, Liang, et al.
Publicado: (2015)

Clinical impact of serum soluble SLAMF7 in multiple myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2018)

Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis
por: Thümmler, Katja, et al.
Publicado: (2022)

Phenotypic Detection of Clonotypic B Cells in Multiple Myeloma by Specific Immunoglobulin Ligands Reveals their Rarity in Multiple Myeloma
por: Trepel, Martin, et al.
Publicado: (2012)

Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma
por: Asher, Samir, et al.
Publicado: (2022)

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
por: De Smedt, Eva, et al.
Publicado: (2018)

Wagner’s theory of generalised heaps
por: Hollings, Christopher D, et al.
Publicado: (2017)

PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION
por: Sridhar, Amrutha, et al.
Publicado: (2023)

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
por: Muylaert, Catharina, et al.
Publicado: (2022)

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma
por: Vlummens, Philip, et al.
Publicado: (2019)

Multiple myeloma presenting as CEA-producing rectal cancer
por: Talamo, Giampaolo, et al.
Publicado: (2010)

MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma
por: Zingoni, Alessandra, et al.
Publicado: (2018)

Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma
por: Łacina, Piotr, et al.
Publicado: (2022)

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma
por: Wang, Jinheng, et al.
Publicado: (2016)

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
por: Oudaert, Inge, et al.
Publicado: (2022)

Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2014)

Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
por: De Beck, Lien, et al.
Publicado: (2018)

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
por: Faict, Sylvia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o1q7rmt0lq160pum3vhe4dpbn0